PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE

PMV Pharmaceuticals (PMVP) announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The Phase 2 clinical trial data below are summarized as of an August 4, 2025 data cutoff date: Efficacy; Confirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma. Overall response rate of 33% per investigator assessment according to Response Evaluation Criteria in Solid Tumors version 1.1, including confirmed and unconfirmed responses. The cohort-specific ORRs were as follows: Ovarian cancer: 43% ORR; Breast cancer: 18% ORR; Endometrial cancer: 60% ORR; Lung cancer: 22% ORR; Other solid tumors: 21% ORR. Across all cohorts, the median time to response was 1.4 months and the median duration of response was 6.2 months. In the ovarian cancer cohort, the median time to response was 1.3 months and median duration of response was 7.6 months